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Can it Be Prevented?*Laura Mauri, MD, MSC,yz Benjamin Z. Galper, MD, MPHyS tent thrombosis (ST) remains a serious compli-cation of percutaneous coronary intervention(PCI), which carries with it a high rate of
morbidity and mortality (1–3). The ﬁrst step in avoid-
ing this problem is understanding how it develops
and what factors might reduce risk. Because ST is,
fortunately, now rare in the setting of optimal proce-
dural technique and dual antiplatelet therapy (DAPT),
it has been difﬁcult to study. Furthermore, early ST
(before 30 days) is more common than later events,
and there have been limited data of both the predic-
tors and consequences of ST in the late and especially
very late periods after PCI (4–8). In this issue of JACC:
Cardiovascular Interventions, Waksman et al. (9)
present the DESERT (Drug-Eluting Stent Event Regis-SEE PAGE 1093try of Thrombosis) study in which they set out to
characterize the clinical predictors and consequences
of late (beyond 30 days) and very late stent throm-
bosis (VLST) (beyond 1 year) after the implantation
of drug-eluting stents (DES). The authors identiﬁed
492 cases of ST from cardiac catheterization labora-
tory procedures and matched these cases to controls
who received a DES in the same institution and on
the same date. This retrospective design provided a
large number of cases of what is generally a rare event
in most prospective studies (e.g., about 1% to 2% over*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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Institutes of Health training grant (T32 HL007604).5 years of follow-up). Clinical and angiographic re-
view and ascertainment of events even beyond 5
years after PCI provided rich data that complement
existing retrospective studies (7), prospective regis-
tries (8), and randomized trials (6).
Cases were selected based primarily on angio-
graphic (rather than post-mortem) evidence of ST.
The study identiﬁed factors present at the time of
initial stent placement that predicted thrombosis
beyond 30 days, many of which are consistent with
prior studies, for example, lesion length, presence of
thrombus, and residual stenosis of the stented
segment. Although previous studies have reported
mortality rates following early or late ST of 20% and
higher (1), the current study (9) reports a rate of 3.8%.
The investigators suggest that the lower mortality
rate seen in late and VLST compared with histori-
cally higher mortality rates in acute and subacute ST is
due to “a different pathological mechanism for this
[VLST] phenomenon.” Another recent registry study
reported a mortality rate of 3.6% to 3.8% (7). Although
it is true that reports before these have focused
primarily on early ST, the more common event, one
must exercise caution in interpreting expectations
regarding the mortality from retrospective analyses
because of limitations in how cases of ST are identiﬁed.
In prospective studies, all patients provide consent for
follow-up, and in most studies to evaluate new de-
vices, near complete follow-up is expected to be per-
formed to ascertain all mortality and causes, and a
committee to review clinical, angiographic, and path-
ological evidence to ascertain ST is mandatory. By
contrast, retrospective studies rely on the ascertain-
ment of cases using various methods. In this example,
cases were ascertained based on presentation for
angiography at the participating study sites. By deﬁ-
nition, cases must have survived to present to the
study site and undergo angiographic conﬁrmation.
Cases of sudden death, which are routinely observed
in prospective studies, would not be captured in this
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1104study (9) or the study by Armstrong et al. (7) because
they would not reach angiography, and as a result,
mortality rates were likely underestimated.
To have an impact on clinical care, a study to
examine risk factors should provide assessment of
which factors might be modiﬁed to decrease risk. Two
key treatment choices in this regard are stent type and
antiplatelet regimen. Regarding DES type, the inves-
tigators observed no effect between earlier and later
designs despite randomized trials supporting lower
late ST rates for current DES compared with prior
designs (6,10,11). Limitations of the available data
might be the cause of this discrepancy from random-
ized trial data. First, lack of power (<10% of subjects
received newer DES), and second, the method used
for selecting cases and controls may have undermined
the ability to examine effects of stent choice. Because
stent type is segregated by calendar time and institu-
tion (e.g., which stents were prevalent in an institution
on a given day), matching cases and controls on site
and day limits the ability to compare the effect of
different stent types. Similar limitations might be
present for comparing the effects of procedural tech-
nique, with operators clustered on the same day.
Intracoronary imaging provided some interesting ob-
servations in the study, but it was not routinely per-
formed at the time of either the index procedure or ST.
As in prior studies, ST occurred in subjects both on
and off of DAPT. It is difﬁcult to compare drug types for
the same reasons that limit stent type comparisons in
this dataset. Regarding whether continuing therapybeyond a certain time could prevent ST, the study 1104
offers limited data. DAPT duration and adherence
were not recorded for controls, and it is not possible,
therefore, to compare DAPT duration and its impact on
ST risk. The true effect of DAPT given beyond 1 year
and ST risk is not well understood currently, but the
ﬁnal follow-up of the DAPT study this year will provide
randomized data comparing a strategy of 1 year versus
longer periods in preventing VLST (12).
Although prospective studies of late ST and VLST
are difﬁcult to conduct because the incidence of late
ST and VLST is low, we must be cognizant of both
the strengths and limitations of retrospective data.
Treatment comparisons beneﬁt from randomization
to avoid selection bias, or the residual bias inherent in
retrospective analysis. Prospective data and compre-
hensive follow-up ensure that hazards and the impact
of risk factors can be accurately estimated. Late
ST and VLST remain serious complications of coro-
nary stenting that, although rare, deserve ongoing
consideration for methods of prevention. The current
study by Waksman and colleagues (9) provides a level
of detail and duration of follow-up as well as a
breadth of patients and procedures that have not
previously been achieved in prospective studies.
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